Sensitive bispecific chimeric T cell receptors for cancer therapy

Stanley R. Riddell(Fred Hutch Cancer Center), Xiaolei Su(Yale University)

Research Square

April 22, 2024

10.21203/rs.3.rs-4253777/v1

Cited by 1

Related Papers

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

|New England Journal of Medicine|1995|1.8k

Phase separation of signaling molecules promotes T cell receptor signal transduction

|Science|2016|1.3k

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

|Blood|2008|719

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

|Blood|2011|600

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

|Blood|2012|530